Open AccessA phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis
Author(s) -
Arthur Jackson,
Jesse C. Nussbaum,
Jacob Phulusa,
Dan Namarika,
Maria Chikasema,
Creto Kanyemba,
Joseph N Jarvis,
Shabbar Jaffar,
Mina C. Hosseinipour,
Charles van der Horst,
Thomas S. Harrison
Publication year - 2012
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e328354b419
Subject(s) - flucytosine , medicine , fluconazole , amphotericin b , meningitis , clinical endpoint , randomized controlled trial , glasgow coma scale , gastroenterology , surgery , antifungal , dermatology
Cryptococcal meningitis in Africa is associated with up to 70% mortality at 3 months and 500 000 deaths annually. We examined strategies to improve on fluconazole (FLU) monotherapy: addition of flucytosine (5-FC) and/or addition of short-course amphotericin B (AmB).